Innovations for the elimination and control of visceral leishmaniasis.
作者信息
Selvapandiyan Angamuthu, Croft Simon L, Rijal Suman, Nakhasi Hira L, Ganguly Nirmal K
机构信息
Institute of Molecular Medicine, Jamia Hamdard, New Delhi, India.
Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
出版信息
PLoS Negl Trop Dis. 2019 Sep 19;13(9):e0007616. doi: 10.1371/journal.pntd.0007616. eCollection 2019 Sep.
Abstract
摘要
相似文献
1
Innovations for the elimination and control of visceral leishmaniasis.
PLoS Negl Trop Dis. 2019 Sep 19;13(9):e0007616. doi: 10.1371/journal.pntd.0007616. eCollection 2019 Sep.
2
Visceral Leishmaniasis Caused by Leishmania donovani Zymodeme MON-37, Western Ghats, India.
Emerg Infect Dis. 2020 Aug;26(8):1956-1958. doi: 10.3201/eid2608.200557.
3
Prevention of Leishmania donovani infection.
BMJ. 2010 Dec 29;341:c6751. doi: 10.1136/bmj.c6751.
4
Incrimination of Phlebotomus (Larroussius) orientalis as a vector of visceral leishmaniasis in western Upper Nile Province, southern Sudan.
Trans R Soc Trop Med Hyg. 1992 Nov-Dec;86(6):622-3. doi: 10.1016/0035-9203(92)90154-5.
5
Vector control interventions for visceral leishmaniasis elimination initiative in South Asia, 2005-2010.
Indian J Med Res. 2012 Jul;136(1):22-31.
6
Revival of a focus of visceral leishmaniasis in central Sudan.
Ann Trop Med Parasitol. 2008 Jan;102(1):79-80. doi: 10.1179/136485908X252269.
7
Control of the leishmaniases. Report of a WHO Expert Committee.
World Health Organ Tech Rep Ser. 1990;793:1-158.
8
Is elimination of kala-azar feasible by 2017?
Indian J Med Res. 2016 Dec;144(6):799-802. doi: 10.4103/ijmr.IJMR_335_16.
9
An overview of visceral leishmaniasis elimination program in India: a picture imperfect.
Expert Rev Anti Infect Ther. 2014 Aug;12(8):929-35. doi: 10.1586/14787210.2014.928590. Epub 2014 Jun 14.
10
[Meeting "Visceral leishmaniasis in Maghreb", 2-4 April 2015 in Tunis. Recommendations].
Bull Soc Pathol Exot. 2015 Aug;108(3):229-30. doi: 10.1007/s13149-015-0435-4.
引用本文的文献
1
Mechanistic insights into LdCen1-LdDRP interaction facilitating UV-induced DNA damage repair in Leishmania donovani.
Med Microbiol Immunol. 2025 Apr 9;214(1):18. doi: 10.1007/s00430-025-00825-3.
2
Design, synthesis and biological activity of peptidyl β-nitrostyrenes as cysteine protease inhibitors against .
RSC Adv. 2025 Feb 19;15(8):5703-5719. doi: 10.1039/d4ra06510g.
3
Robust leishmanicidal upshot of some new diphenyl triazine-based molecules.
RSC Adv. 2024 Jul 17;14(31):22587-22597. doi: 10.1039/d4ra01904k. eCollection 2024 Jul 12.
4
Manufacturing and preclinical toxicity of GLP grade gene deleted attenuated Leishmania donovani parasite vaccine.
Sci Rep. 2024 Jun 25;14(1):14636. doi: 10.1038/s41598-024-64592-6.
5
Biophysical Evidence for the Amyloid Formation of a Recombinant Rab2 Isoform of .
Protein Pept Lett. 2024;31(4):312-322. doi: 10.2174/0109298665299157240327084614.
6
Portable smartphone-based molecular test for rapid detection of Leishmania spp.
Infection. 2024 Aug;52(4):1315-1324. doi: 10.1007/s15010-024-02179-z. Epub 2024 Feb 14.
7
Evaluation of a Point-of-Need Molecular Diagnostic Tool Coupled with Rapid DNA Extraction Methods for Visceral Leishmaniasis.
Diagnostics (Basel). 2023 Dec 11;13(24):3639. doi: 10.3390/diagnostics13243639.
8
Antimony resistance and gene expression in : spotlight on molecular and proteomic aspects.
Parasitology. 2024 Jan;151(1):1-14. doi: 10.1017/S0031182023001129. Epub 2023 Nov 28.
9
Visceral Leishmaniasis Associated with HIV Coinfection in Pará, Brazil.
HIV AIDS (Auckl). 2023 May 25;15:247-255. doi: 10.2147/HIV.S400189. eCollection 2023.
10
Limitations of current chemotherapy and future of nanoformulation-based AmB delivery for visceral leishmaniasis-An updated review.
Front Bioeng Biotechnol. 2022 Dec 14;10:1016925. doi: 10.3389/fbioe.2022.1016925. eCollection 2022.
本文引用的文献
1
Development of a Multiplexed Assay for Detection of and Protein Biomarkers in Urine Samples of Patients with Visceral Leishmaniasis.
J Clin Microbiol. 2019 Apr 26;57(5). doi: 10.1128/JCM.02076-18. Print 2019 May.
2
Eliminating visceral leishmaniasis in South Asia: the road ahead.
BMJ. 2019 Jan 22;364:k5224. doi: 10.1136/bmj.k5224.
3
A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
PLoS Negl Trop Dis. 2019 Jan 17;13(1):e0006988. doi: 10.1371/journal.pntd.0006988. eCollection 2019 Jan.
4
Age trends in asymptomatic and symptomatic Leishmania donovani infection in the Indian subcontinent: A review and analysis of data from diagnostic and epidemiological studies.
PLoS Negl Trop Dis. 2018 Dec 6;12(12):e0006803. doi: 10.1371/journal.pntd.0006803. eCollection 2018 Dec.
5
Validation of SYBR green I based closed tube loop mediated isothermal amplification (LAMP) assay and simplified direct-blood-lysis (DBL)-LAMP assay for diagnosis of visceral leishmaniasis (VL).
PLoS Negl Trop Dis. 2018 Nov 15;12(11):e0006922. doi: 10.1371/journal.pntd.0006922. eCollection 2018 Nov.
6
Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies.
Clin Infect Dis. 2019 Jul 2;69(2):251-258. doi: 10.1093/cid/ciy891.
7
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.
Clin Microbiol Rev. 2018 Aug 29;31(4). doi: 10.1128/CMR.00048-18. Print 2018 Oct.
8
New insights into leishmaniasis in the immunosuppressed.
PLoS Negl Trop Dis. 2018 May 10;12(5):e0006375. doi: 10.1371/journal.pntd.0006375. eCollection 2018 May.
9
A defined subunit vaccine that protects against vector-borne visceral leishmaniasis.
NPJ Vaccines. 2017 Aug 21;2:23. doi: 10.1038/s41541-017-0025-5. eCollection 2017.
10
Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
PLoS Negl Trop Dis. 2017 Nov 16;11(11):e0005877. doi: 10.1371/journal.pntd.0005877. eCollection 2017 Nov.
Zotero 插件